Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

tDCS to Decrease Opioid Relapse (UH3)

NCT: NCT06432465 · RECRUITING

NCT IDNCT06432465
StatusRECRUITING
Start Date2024-04-17
Completion2026-12-31
SponsorButler Hospital (OTHER)
First posted
Last updated

Brief Summary

Investigators will measure behavioral and brain responses following transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (DLPFC) (anode on right DLPFC, cathode on the left DLPFC) delivered during cognitive control network (CCN) priming. In Phase I, the EEG provided validation of expected changes in these networks following tDCS stimulation of the DLPFC. In this current phase (II), the investigators will perform a larger randomized clinical trial (RCT) (active vs. sham control) to address long-term neurobehavioral outcomes, including opioid relapse, craving, and sustained EEG changes.

Frequently Asked Questions

What is tDCS to Decrease Opioid Relapse (UH3)?

tDCS to Decrease Opioid Relapse (UH3) is a clinical trial registered under NCT06432465. Current status: RECRUITING.

What is the status of NCT06432465?

The current status of NCT06432465 (tDCS to Decrease Opioid Relapse (UH3)) is: RECRUITING.

When did tDCS to Decrease Opioid Relapse (UH3) start?

tDCS to Decrease Opioid Relapse (UH3) started on 2024-04-17.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.